V ascular dementia (VAD) is the second most common cause of dementia after Alzheimer and accounts for at least 20% of dementia cases. Lesser degrees of cognitive decline because of cerebrovascular disease are even more common, and the umbrella term vascular cognitive impairment (VCI) has been introduced to cover all degrees of cognitive impairment because of cerebrovascular disease, from mild impairment through to dementia. 1 In the same way that stroke is a heterogeneous disease caused by multiple different pathological processes, VCI also results from many different vascular pathologies. In principle, any disease process causing cerebral ischemia or hemorrhage can cause VCI. Neuroimaging and pathological studies have allowed division of VCI mechanisms into several broad groups, including multiple infarcts, single strategic infarcts, intracerebral hemorrhage, hypoperfusion, and cerebral small vessel disease (SVD). 1 It is now recognized that by far the most common pathology underlying VCI is cerebral SVD, 1 which is most readily seen on magnetic resonance imaging (MRI) as white matter hyperintensities (WMHs) and lacunar infarcts although other features which may contribute to cognitive decline include atrophy and cerebral microbleeds. In addition, many of the pathologies causing SVD also predispose to intracerebral hemorrhage which itself can contribute to cognitive decline. The most popular hypothesis is that these diverse subcortical pathologies lead to damage to white matter pathways, which disrupts complex distributed corticalsubcortical circuits underlying cognitive processes, such as executive function and processing speed. 2 Cerebral amyloid angiopathy (CAA) also affects the cerebral small vessels and causes intracerebral hemorrhage and has been associated with VCI and dementia. 1 
How Could Genetic Predisposition Increase VCI Risk?
Although perhaps oversimplistic, a useful distinction can be made between genetic risk factors which increase the risk of the underlying pathologies causing VCI (such as SVD) and risk factors which alter the way in which the brain responds to these vascular insults. Latter factors could include not only neuronal responses to brain injury and mechanisms associated with plasticity but also factors altering cognitive brain reserve.
For example, it has been shown that a greater number of years in full-time education is associated with a reduced dementia risk and this has been thought of as increased cognitive reserve, while genetic variants associated with education attainment have been associated with a reduced risk of dementia. 3 Currently, almost all data on VCI genetic risk have looked at the underlying stroke and cerebrovascular disease mechanisms. The fact that all monogenic forms of VAD result from gene mutations which alter arterial function, predominantly small cerebral arteries, suggests that this may be the dominant genetic mechanism leading to VCI.
Are Genetic Risk Factors Important for VCI?
There is little data from twin and other epidemiological studies estimating the heritability of VAD with only a small twin study, which was too underpowered to be conclusive. 4 However, increasing evidence from both epidemiological and genetic studies suggests that the pathological processes underlying VAD have significant heritability. Heritability estimates obtained from GWAS (Genome-Wide Association Study) have reported heritability of 20% to 40% for large artery, cardioembolic, and small vessel stroke. 5, 6 Furthermore, the radiological features of SVD, the major pathology underlying VCI, have been shown to have high heritability. Twin and family studies estimate the heritability of WMH lesion volume to be between 50% and 80%, 7, 8 Perhaps the strongest evidence that genetic factors can cause VAD comes from the range of monogenic conditions which result in small artery stroke and VAD. (Table) Such monogenic diseases tend to cause VCI and VAD in middle age. In this article, we will first review monogenic conditions predisposing to VAD and then cover recent insights into pathogenesis of apparently sporadic VCI.
Monogenic Forms of SVD
The most common familial form of SVD is cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), caused by mutations in the NOTCH3 gene, a single pass transmembrane protein belonging to an evolutionarily conserved NOTCH receptor family. 9 Typical features include migraine, usually with aura, occurring in the 20s or 30s, lacunar strokes occurring in middle age, and
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VCI which may progress to VAD. 10 Other common features include an encephalopathy which can be the presenting feature in 10% of individuals, apathy, and depression. 10 MRI findings ( Figure 1 ) share many features with sporadic SVD, including lacunar infarcts, confluent WMH, enlarged perivascular spaces, cerebral microbleed, and atrophy. However, the spatial pattern of WMH, particularly the involvement of the anterior temporal pole, is a useful diagnostic pointer. 11 Although originally thought to occur predominantly in individuals without stroke risk factors, it is now well recognized that vascular risk factors, particularly smoking and hypertension, interact with the NOTCH3 mutation to cause earlier onset disease. 10, 12 For example, CADASIL patients who smoke on average have stroke 10 years earlier. 10 Therefore, careful control of cardiovascular risk factors is important.
An autosomal recessive form of familial SVD was first described in consanguineous Japanese and Chinese families, and the underlying gene was identified as HtrA serine peptidase 1 (HTRA1). 13 Such individuals also suffer multiple lacunar strokes, which could lead to VCI, although other systemic features occur, including alopecia and low back pain. A heterozygous form of the disease because of a single HTRA1 AD indicates autosomal dominant; AR, autosomal recessive; CADASIL, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy; CMB, cerebral microbleed; EGFr, epidermal growth factor-like repeat region; Foxc1, Forkhead box transcription factor C1; HtrA1, high temperature requirement serine protease A1; MRI, magnetic resonance imaging; RVCL-S, retinal vasculopathy with cerebral leukodystrophy and systemic manifestations; SVD, small vessel disease; TGF, transforming growth factor; TREX1, Three prime repair exonuclease; VCI, vascular cognitive impairment; and WMH, white matter hyperintensity. mutation has recently been recognized 14 and this seems to be the second most common mutation underlying familial SVD after NOTCH3 in the United Kingdom. (Hugh Markus, unpublished data.) It is associated with a similar phenotype to autosomal recessive CARASIL, with lacunar stroke, confluent WMH and sometimes encephalopathy, and VCI. However, the age of presentation seems to be later and systemic features, such as alopecia and back pain, are less frequent. 14 Mutations in collagen type IV α 1 chain (COL4A1) or COL4A2 affecting basal membrane integrity can cause familial SVD. 15 Both intracerebral hemorrhage, as well as lacunar stroke and WMH, are seen. The disease can also present with porencephaly in childhood, as well as eye and retinal involvement. Cerebral microbleeds are particularly frequent on MRI, reflecting the increased prevalence of intracerebral hemorrhage. 16 Other rarer single gene disorders have also been associated with SVD, including mutations in three prime repair exonuclease 1 (TREX1) and Forkhead box C1 (FOXC1) 17 (Table) . Mutations causing CAA can also be associated with VCI. Monogenic forms are caused by APP (amyloid precursor protein) mutations. Mutations at codon 693 cause amino acid substitutions at position 22 of amyloid-β. 18 There is hereditary cerebral hemorrhage with amyloidosis-Dutch type in which a Glu to Gln exchange leads to CAA with recurrent lobar hemorrhages and white matter damage. 19 At the same position, a Glu to Lys exchange was been described in Italian families with multiple strokes, 19 and a Glu to Gly exchange is characteristic for the Arctic type early-onset Alzheimer disease (AD) which was reported in Swedish families. 20 The Flemish mutation affects codon 692. 21 Codon 694 is typically affected in CAA of the Iowa type. 22 It is of note that familial AD cases caused by mutations in presenilin 1 or presenilin 2 genes also have severe CAA particularly if they occur behind codon 200. 23 
Sporadic VCI
Relatively few studies have investigated genetic risk factors for sporadic VCI itself as an outcome: many more have looked for risk factors underlying the contributing pathological processes, such as all stroke, small artery stroke, and radiological markers of SVD.
Over the past 2 decades, GWAS has transformed our understanding of the genetics of complex diseases including stroke. A major advantage of GWAS is that, by the use of hundreds of thousands of markers spanning the whole genome, entirely novel associations can be detected and no prior hypothesis is required. However, the multiple statistical comparisons made mean that large sample sizes, 1000s or 10s of 1000s, are required, and such datasets are currently scarce in VCI. To date, only 2 small GWASs have been reported with VAD as the outcome measure. A retrospective study in Korea (84 patients; 200 controls) detected no associations but was underpowered 24 ; GWAS studies of complex diseases tend to require sample sizes in the 1000s to detect significant associations. A prospective study in the Netherlands (67 patients; 5700 controls) identified an association with the variant rs12007229 near the androgen receptor gene on the X chromosome: this was replicated in the German population of 221 cases and 213 controls. 25 However, replication in a much larger sample size is required.
An alternative but less powerful approach is the candidate gene approach. Here a variant in a gene suspected of being associated with the disease in question is identified, and a study performed to determine whether the variant is more common in disease cases compared with controls. However, candidate gene studies in many complex diseases including stroke have produced results which have failed to be replicated in GWAS studies involving many 1000s of individuals, suggesting the underlying methodology was often not robust. Particular issues have included small sample sizes which we now in the GWAS era realize were too small, poor phenotyping, and publication bias with selective reporting of positive studies, and multiple testing of different polymorphisms without correction for multiple testing.
Several meta-analyses have reviewed candidate gene studies in VCI, but caution in their interpretation is required as they cannot fully overcome poor methodology, including publication bias, in the contributing studies. Two meta-analyses assessed single nucelotide polymorphism associations with VCI and VAD. In one increased risk for VCI was found for APOE ε4 (apolipoprotein E) and MTHFR (methylenetetrahydrofolate reductase) polymorphisms. 26 The second study 27 included 69 studies with 4462 cases and 11 583 controls and identified APOE ɛ2/ɛ3/ɛ4, MTHFR C677T, PON1 (paraoxonase 1) L55M, TGF-β1 (transforming growth factor-β1) +29C/T, and TNF-α (tumor necrosis factor-α) −850C/T with VAD. A third meta-analysis focused on APOE and identified 29 studies, including 1763 VAD cases and 4534 controls. 28 Overall, APOE and MTHFR polymorphisms are the most consistently found single nucelotide polymorphisms to be associated with VCI. Analysis of APOE ε2 revealed a significant protective effect against VAD in only one of the metaanalyses. 28 APOE has also been reported to be related to MRI correlates of SVD, including WMH. 29 A potential issue in interpreting results from studies with VAD as the clinical end point relates to diagnosis. Until recently, international definitions for VAD required impairment 
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of episodic memory, which can often be a later feature of VAD because of SVD, but is more commonly seen early in the course of AD. 1 This, combined with the well-recognized observation that many cases of dementia in the elderly have mixed pathology, including both vascular and AD pathology, mean that determining whether associations are specifically with VAD or could be because of genetic risk factors contributing to associated AD pathology can be difficult. More progress is likely to be made with studies in which accurate phenotyping is performed with neuroimaging to look at the type and extent of vascular changes, as well as the updated dementia classifications 1 which allow VAD cases to be included if cognitive deficits occur in a variety of different domains, including executive function.
Genetic Influences for Sporadic Stroke
In contrast to the little GWAS data on VCI, there is now increasing data on stroke, which is likely to be also relevant for VCI. A series of international collaborative GWAS studies in ischemic stroke (WTTCC2, 30 METASTROKE, 31 and MEGASTROKE 32 ) have identified 32 loci associated with ischemic stroke. A striking early finding was that many of the variants identified predisposed to individual stroke subtypes, 31 emphasizing that different ischemic stroke subtypes have different genetic architecture. The recent MEGASTROKE analysis in 67 162 cases and 454 450 controls also identified a number of genes predisposing to conventional cardiovascular risk factors known to increase stroke risk. 32 Interestingly, genetic variants predisposing to thrombosis have been associated with an increased risk of thromboembolic stroke secondary to large artery disease and cardioembolism, but not of small artery stroke, suggesting that thrombotic factors may be less important for SVD. 32, 33 Any of the genes identified as predisposing towards ischemic stroke are likely to increase the risk of VCI, as all stroke subtypes can lead to cognitive impairment. However, the most import in terms of contribution to VCI is likely to be genes predisposing to SVD because this is the major pathology underlying VCI. Unlike large artery and cardioembolic stroke for which many GWAS loci have been identified, there has been only one GWAS association with small vessel stroke. In 4203 small vessel strokes and 50 728 controls, an association was found with a locus on chromosome 16q24.2. 34 The same locus was associated with WMH. 34 The small number of GWAS loci identified in SVD is likely to represent methodological issues. Many cohorts have used loose definitions for lacunar stroke including a lacunar syndrome with a normal CT scan, and it has been shown that up to 50% of such cases may not have SVD. 35 Accurate phenotyping with MRI increases the yield in genetic studies. 5 Current international collaborations are collecting large cohorts of MRI phenotyped SVD cases for GWAS.
Increasing evidence has highlighted the importance of endothelial dysfunction and blood-brain barrier disruption in SVD. 36, 37 Epidemiological studies have shown an association between homocysteine levels and ischemic stroke, and its has been reported this may be particularly with SVD. 38 However, determining whether this association is causal or confounded by other factors is challenging. 39 Genetic techniques can be useful in investigating causality using the technique called Mendelian randomization. Here a genetic variant associated with increased level of the blood marker in question is identified and if it is associated with disease this provides evidence that the association is indeed causal because the genetic variant has exposed the individual to increased levels of the marker in question throughout their life. Therefore, the association of the MTHFR polymorphism, which increases homocysteine levels, suggests that homocysteine may be a causal risk factor in SVD. 40 It has been suggested this acts via affects on small vessel endothelial function. 38 Several GWAS studies have been performed in patients with MRI markers of SVD, particularly WMH, 41, 42 and many loci associated with WMH, as well as a loci associated with white matter ultrastructural damage identified on diffusion tensor imaging. 43 
Genetics of Sporadic CAA
Most cases of CAA are sporadic. It is present in ≈10% to 40% of elderly brains and 80% of patients with AD. 44 For CAA-related intracerebral hemorrhage the estimated heritability is 70%. 45 Yet, APOE ε4 and ε2 alleles are the only genetic risk factors that have been robustly associated with risk of developing sporadic CAA. 46 APOE ε4 increases the risk for CAA and APOE ε2 was shown to be a risk factor for intracerebral haemorrhage in Ab-CAA patients. 47 Although the exact reasons for the association of CAA with APOE ε4 are not fully determined, it is possible that APOE ε4 is associated with fibrillogenesis of Ab within brain tissue and in perivascular drainage pathways. 48 Also, APOE ε4 binds to LRP-1(low density lipoprotein receptor-related protein 1) and interacts with soluble and aggregated Ab both in vitro and in vivo, influencing its conformation and clearance. 49 The AD-related locus, CR1 (complement component receptor 1), was reported to influence CAA-ICH incidence and recurrence while hypertension loci play no significant role in CAA-related intracerebral hemorrhage. 45 The association of CAA with cognition has been debated. Several studies suggest a link between CAA and dementia, 50 but there have also been clinicopathological studies like the Honolulu Asia Aging Study 51 in which CAA was associated with cognition only in the presence of AD, questioning the degree to which CAA makes a separate contribution to dementia. In the Rush Memory and Aging Project and the Religious Orders Study, 52 it was shown, however, that CAA affects cognitive outcomes over and above the main causes of dementia and that CAA was associated with a faster rate of decline in cognition. Hemorrhagic and ischemic brain abnormalities are likely to contribute to CAA-related cognitive decline. These include recurrent intracerebral hemorrhages, cerebral microbleed, superficial cortical siderosis, convexal subarachnoid hemorrhage, brain infarcts, white matter lesions, and microstructural tissue damage. The figure gives examples of CAArelated brain abnormalities on MRI (Figure 2) .
What Are the Implications of Genetics for VAD Care?
In the small group of patients with monogenic conditions underlying VCI, diagnosis can be important both in guiding management and prognosis. In the past screening for these disorders has been time consuming, and not always widely available with each individual disorders requiring Sanger sequencing of that individual gene, but with the advent of next-generation sequencing arrays it is now possible to screen for all possible SVD genes in one assay. Diagnosis also allows the possibility of presymptomatic and prenatal testing within families. 
Stroke
March 2019
In the much more common multifactorial VAD, in which genetic influences are likely to be polygenic (ie, resulting from multiple genes each contributing a small increase in risk likely interacting with environmental risk factors), there is hope that genetic risk profiling may allow prediction of a group at high risk in whom particular preventative or therapeutic strategies could be performed. This is beginning to look promising in other complex diseases in which a significant genetic component has been identified, for example, coronary artery disease. 53 However, the limited information we currently have on the genetics of VAD makes such risk prediction impossible at the present time.
Perhaps more importantly future better understanding of the genetics of VAD may allow us to gain new insights into the underlying therapeutic processes and, therefore, develop better-targeted treatment approaches.
Insights Into the Pathogenesis of SVD and Vascular Dementia From Genetic Studies
Recent studies in monogenic SVD are providing exciting insights into underlying disease processes underlying both SVD and VCI. 17 They have provided evidence for an involvement of key ECM (extracellular matrix) or matrisome proteins in pathogenesis. 17, 54 The ECM comprises the noncellular component of tissues made up of water, proteins, and polysaccharides, which provide scaffolding for cellular components by producing fibrous proteins, such as collagen, elastin, and laminin. It is also biochemically active providing signals which contribute to tissue function and homeostasis. The matrisome is defined as the ensemble of nearly 300 proteins which make up the ECM (core matrisome), or are associated with the ECM (matrisome-associated proteins), and these have been characterized by proteomic and bioinformatic methods. 17 Evidence is emerging suggesting monogenic types of SVD disrupt matrisome function. This has been best illustrated in CADASIL by an elegant series of experiments. Postmortem studies in CADASIL report aggregation of key matrisome proteins. 55 Studies in a transgenic CADASIL mouse led to the hypothesis that NOTCH3 mutations result in aggregation of aberrant portions of the extracellular NOTCH3 protein, 56 which itself induces a cascade of aggregation of other matrisome proteins, including TIMP3 (tissue inhibitor of metalloproteinase 3), which promotes sequestration of other matrisome proteins including vitronectin. 57 Such a cascade can result in a potassium channelopathy and impaired cerebrovascular reactivity which itself could lead to cerebral ischemia. 57 One of the matrisome proteins identified in NOTCH3 extracellular protein aggregates in CADASIL has also been identified as a key molecule in CARASIL. LTB-1 (latent TGFB-binding protein1), which was found to coaggregate with NOTCH3 extracellular in CADASIL, was identified to be a target of the HTRA1 protease in a study in mouse and patient tissues. 58 Other mutations such as COL4A1/2 lead to direct disruption of ECM components, in this case the collagen scaffold. 54 Taken together this evidence suggests that different mutations underlying monogenic SVD may causes SVD shared molecular pathways leading to matrisome dysfunction. The finding that common genetic variants in both COL4A1/2 59 and HTRA1 32 also increase risk of sporadic SVD and WMH suggests that similar molecular processes also play a role in sporadic SVD and, therefore, may be of much larger importance to SVD and VCD. Excitingly this has led to potential targets, and intervening in the process has been shown to delay the pathological cascade in a transgenic CADASIL model. 57 
Conclusions and the Future
The predominant importance of SVD in causing VCI is now well recognized, and an increasing number of monogenic forms of SVD and VCI are being identified. New next-generation sequencing techniques are transforming our ability to make this diagnosis. Insights provided by experimental models of monogenic SVD, as well as from studies in man and models of sporadic SVD, are transforming our understating of SVD and VCI. They are emphasizing the importance of disruption of the matrisome, as well as the role of endothelial dysfunction and blood-brain barrier dysfunction in the pathogenesis of SVD. These insights are presenting new treatment possibilities. Whether additional genetic factors determine whether a person with stroke or SVD, will develop VCI remains largely unknown, and understanding this will require large-scale GWAS and other studies, similar to those which have made such progress in the understanding the genetic basis of stroke and other complex diseases. 
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